Dosage Forms

Novavax announces DoD contract to produce 10 million doses of COVID-19 vaccine candidate.

SiO2 Materials Science has received $143 million from the US government to accelerate capacity scale-up of its advanced primary packaging platform.

The European Commission has granted marketing authorization to the Janssen Pharmaceutical Companies of Johnson & Johnson for Darzalex (daratumumab) subcutaneous formulation to treat adults with multiple myeloma.

CordenPharma announces expansion of lipid excipients supply for coronavirus vaccine scale up.

Agreements with the PolyPeptide Group and AGC Biologics will scale up production of the Novavax Matrix-M adjuvant.

Achieving herd immunity will require testing, data, a vaccine, and public support.

The correct mix of excipients is crucial to the success of fast dissolving/orally disintegrating dosage forms.

Merck will use Themis’s vector platform to develop a vaccine to prevent COVID-19.

Merck will acquire Themis Bioscience and collaborate with IAVI and Ridgeback Bio on COVID-19 vaccines and therapies.

CordenPharma and Moderna extended a strategic manufacturing services agreement for the supply of lipid excipients to be used in Moderna’s vaccine against SARS-CoV-2.

HHS announces $354 million in funding for private industry to manufacture generic drugs in the US from raw materials to finished product.

Evonik opened a new facility for GMP manufacturing of bioresorbable polymers and excipients for pharmaceutical and medical applications in Birmingham, AL.

As a result of the rising use and development of biological drugs, the biopharma industry is witnessing an increase in the adoption of prefilled syringes.

Single-use processing requires instruments providing the accuracy of traditional technologies but configured in form factors designed specifically for this service

Will moving at “warp speed” to develop a vaccine impact efficacy or safety?

Equipment and process optimization must be considered for scaling up these developmental technologies to commercial production.

Many antibody-drug conjugate therapies are in the pipeline; however, only a handful have been approved. What are the bottlenecks?

Reformulation strategies can provide drug developers with a head start to achieve promising options that benefit the patient.

Industry opportunities are increasing for biosimilars, but companies should pay close attention to delivery device design to facilitate success.

A quick look at the history of OTC dosage form development shows the importance of patient-centered innovation.

Mannitol has been shown to improve patient perceptions of tablet flavor and mouthfeel, but its use can add to tableting challenges. SPI Pharma has developed new grades of material designed to make it easier to manufacture in patient-centered formulations.

Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.

The new molecules entering the development pipeline are bringing forth exciting challenges in drug delivery.

Risk levels should be considered when designing containment for pharmaceutical tableting equipment to enhance operator safety.

With new tests showing NDMA levels increase under normal storage conditions, FDA calls for removal of ranitidine products from the market.

Understanding formulation properties early in development can prevent some costly issues later on.

OSD forms are popular within the industry due to the various advantages they offer, but there are specific considerations required to get the best OSD form possible.

This article examines multi-tip tool technology for pharmaceutical tablet compression and the process control and validation issues that must be carefully evaluated to assess the potential for success.

Tools help improve understanding of excipient risk in formulating OSD drugs.

Understanding European GMPs and new rules from China for excipients are crucial for formulating solid-dosage drugs.